TICKERNERD
Menu
MDGLMDGLHealthcare · Biotechnology

MDGL Stock Forecast: Madrigal Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 27 Oct 2026
$440
+0.59% on the day

The 19 Wall Street analysts covering Madrigal Pharmaceuticals, Inc. hold a median 12-month price target of $662 — +50.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 26 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$10.0B
Ticker Nerd rank
70/ 100
Median analyst target
$662
Analysts covering
19
Revenue$364.3M+71.2% y/y
Operating income−$56.3M
Net income−$57.9M
Free cash flow$19.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.8%
1M
−14.8%
YTD
−24.4%
1Y
+1.0%
From 52W high
−27.0%
From 52W low
+6.8%
$412
$603
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MDGL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Madrigal Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 26 Oct 2026
70/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Value
93
Quality
86
Revisions
86
Momentum
62
Growth
45
Accruals
41
Size
15
Issuance
13

Volatility (98): The share price has been relatively steady.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MDGL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MDGL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$500$600$700$800$900$1,000Jan 26Apr 26Jul 26Oct 26MDGLHigh $962Median $662Low $533

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
18 Buy1 Hold0 Sell
Low $533Median $662High $962

The green dot is the last close — the median target sits +50.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
24 Sept 2026Goldman SachsReinstatesBuy$704
23 Sept 2026CitigroupInitiatesBuy$725
4 Aug 2026Wolfe ResearchUpgradeOutperform$605
4 Aug 2026Wolfe ResearchUpgradeOutperform—
3 Aug 2026BarclaysMaintainsOverweight$964 → $962
3 Aug 2026BarclaysMaintainsOverweight—
29 July 2026Canaccord GenuityMaintainsBuy$578 → $587
29 July 2026Canaccord GenuityMaintainsBuy—
27 July 2026Wells FargoInitiatesOverweight$685
27 July 2026Wells FargoInitiatesOverweight—
11 June 2026B of A SecuritiesMaintainsNeutral$550 → $542
11 June 2026B of A SecuritiesMaintainsNeutral—
13 May 2026Truist SecuritiesMaintainsBuy—
7 May 2026Canaccord GenuityMaintainsBuy—
7 May 2026Evercore ISI GroupMaintainsOutperform—
6 May 2026HC Wainwright & Co.ReiteratesBuy—
20 Feb 2026B of A SecuritiesMaintainsNeutral—
28 Jan 2026BarclaysInitiatesOverweight—
20 Jan 2026CitizensMaintainsMarket Outperform—
19 Dec 2025Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MDGL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

MDGL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 27 Oct 2026, Madrigal Pharmaceuticals, Inc. returned +1.0% against +12.9% for the S&P 500, dividends included.

MDGL vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26MDGLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MDGL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Madrigal Pharmaceuticals, Inc. (MDGL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−33.8×

Cheaper than 98% of US stocks

Price / sales
7.8×

Cheaper than 16% of US stocks

Price / book
19.1×

Cheaper than 5% of US stocks

EV / EBITDA
−29.7×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
71.2%

Higher than 90% of US stocks

Earnings growth (YoY)
71.2%

Higher than 80% of US stocks

Gross margin
89.0%

Higher than 96% of US stocks

Operating margin
−15.5%

Higher than 23% of US stocks

Net margin
−25.3%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−53.3%

Higher than 21% of US stocks

Return on assets
−17.8%

Higher than 21% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Madrigal Pharmaceuticals, Inc. (MDGL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Madrigal Pharmaceuticals, Inc. has a market value of $10.0B and an enterprise value of $9.5B.

  • Revenue in the twelve months to 30 June 2026: $1.3B. The latest quarter grew 71.2% year on year.

  • Net income over the same four quarters: −$325.1M, a −25.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−12.89.

  • Free cash flow in the twelve months to 30 June 2026: −$209.3M.

  • Shares outstanding: 23.1M.

  • Trailing P/E: −33.8×; forward P/E: 45.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Madrigal Pharmaceuticals, Inc. employs 915 people — $1.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 27 Oct 2026

Data provided by Twelve Data

Peers

MDGL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MDGLMadrigal Pharmaceuticals, Inc.$10.0B70
TWSTTwist Bioscience Corp.$9.6B70
KYMRKymera Therapeutics, Inc.$9.5B82
PCVXVaxcyte, Inc.$9.4B55
CORTCorcept Therapeutics, Inc.$9.4B68
BMRNBioMarin Pharmaceutical, Inc.$10.8B54
KRYSKrystal Biotech, Inc.$9.3B74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Madrigal Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MDGL news & analysis

Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know

Zacks Investment Research · 27 Oct 2026negative

Zacks Investment Research says Madrigal lacks the combination of two key ingredients associated with a likely earnings beat ahead of its upcoming report. The headline asks whether the company will report negative earnings next week, while the excerpt provides no earnings figures or confirmed outcome.

Why it matters — MDGL watchers may note the article’s cautious framing of expectations for the upcoming earnings report.

Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH

GlobeNewsWire · 27 Oct 2026positive

Madrigal announced that new clinical and real-world evidence on Rezdiffra will be presented at AASLD’s The Liver Meeting, Nov. 5–9, 2026. Topics include effectiveness, tolerability, treatment persistence, noninvasive treatment-response measures, cardiovascular risk markers and patient-reported outcomes; the largest real-world dataset covers more than 12,000 patients.

Why it matters — The presentations will provide additional clinical-practice evidence on Rezdiffra, including data on its use and patient outcomes.

Baron Health Care Fund: Q3 2026 New Positions And Exits

Seeking Alpha · 26 Oct 2026negative

Baron Health Care Fund reported that it sold Madrigal Pharmaceuticals during Q3 2026 to manage risk ahead of a competitor’s clinical trial readout. The Fund added four new positions and exited 14, ending the quarter with 33 positions.

Why it matters — The disclosure indicates that the Fund’s exit from MDGL was tied to risk management ahead of a competitor’s trial readout.

Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise

Seeking Alpha · 20 Oct 2026positive

Madrigal reported Q2 net sales of $364.3 million, up 71%, with Rezdiffra serving more than 50,000 patients and gross margins of 89%. The article says recurring cash operations are around breakeven or slightly positive despite a headline loss, while cash balances increased.

Why it matters — The report highlights Rezdiffra’s commercial progress and its potential to support Madrigal’s ongoing commercial and pipeline investments ahead of key 2027 data.

FAQ

Frequently asked questions about MDGL stock

What is the MDGL stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Madrigal Pharmaceuticals, Inc. have a median 12-month price target of $662, with estimates ranging from $533 to $962. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MDGL stock a buy right now?

Of the 19 analysts covering Madrigal Pharmaceuticals, Inc., 18 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Madrigal Pharmaceuticals, Inc. 70 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MDGL?

As at 26 Oct 2026, Madrigal Pharmaceuticals, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will MDGL stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +50.2% from the last close, and Ticker Nerd's factor model ranks Madrigal Pharmaceuticals, Inc. 70 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MDGL stock forecast for 2030?

No analyst covering Madrigal Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $533 to $962 over the next 12 months.

How has MDGL stock performed over the past year?

Madrigal Pharmaceuticals, Inc. returned +1.0% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Madrigal Pharmaceuticals, Inc. do?

Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need.

What is the latest news on MDGL?

The most recent item we track (Zacks Investment Research, 27 Oct 2026): "Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know". Zacks Investment Research says Madrigal lacks the combination of two key ingredients associated with a likely earnings beat ahead of its upcoming report. The headline asks whether the company will report negative earnings next week, while the excerpt provides no earnings figures or confirmed outcome.

Company

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. Its lead product, Rezdiffra, is a once-daily oral therapy designed to address the underlying biology of MASH in adults with moderate to advanced liver fibrosis. The company’s current business is centered on liver disease, with a commercial presence supported by medical affairs, patient support, and market access activities. Madrigal Pharmaceuticals Inc. also maintains research and clinical development efforts around thyroid hormone receptor-beta science, reinforcing its role as a specialist company in hepatology and metabolic medicine. Based in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals Inc. serves a focused segment of the biopharmaceutical market that targets chronic liver and metabolic disorders.

CEO Mr. William J. Sibold · 915 employees · United States · https://www.madrigalpharma.com